• Methyl-β-cyclodextrin Workflow Guide

  2026-09-01

  Methyl-β-cyclodextrin (SKU C6939) provides a controllable reagent strategy for membrane cholesterol extraction and related studies of lipid organization, membrane fluidity, and signaling. It is for controlled scientific research only; working concentration, exposure time, and biological effects must be established in the investigator’s own assay rather than inferred from a universal protocol.

• GSH and GSSG Assay Kit for Tumor Redox Research

  2026-09-01

  Translate hypoxia and immunometabolism questions into quantitative redox endpoints with matched total glutathione, GSH, and GSSG measurements. This practical workflow highlights sample handling, selective GSSG analysis, matrix control, and troubleshooting across tumor, immune, tissue, plasma, and cell models.

• GSK2606414: From PERK Mechanism to Translation

  2026-08-31

  A translational perspective on GSK2606414 as a selective PERK inhibitor, connecting ER stress biology with PERK-dependent pyroptosis, assay design, cancer research, and disease-model strategy.

• ATM Inhibition and Fenofibrate in HGSOC

  2026-08-31

  The reference study identifies a metabolism-linked vulnerability in high-grade serous ovarian cancer (HGSOC): ATM suppression enhances the activity of fenofibrate, a PPARα agonist, in ATM-low cellular contexts. Its principal contribution is to connect DNA damage response inhibition with metabolic intervention and senescence, suggesting a combination strategy that may extend beyond tumors with homologous recombination deficiency.

• Azathramycin A: From Ribosome Binding to TB Translation

  2026-08-30

  Azathramycin A offers translational researchers a mechanistic probe for studying macrolide-driven disruption of Mycobacterium tuberculosis protein synthesis. This thought-leadership guide connects ribosome engagement, degradation-state control, matrix-aware assay design, PK/PD reasoning, and antibiotic resistance research while clearly separating research opportunity from clinical evidence.

• MG-262 Proteasome Inhibition: Practical Workflows

  2026-08-29

  MG-262 enables time-controlled proteasome inhibition in intact cells, making it useful for ubiquitin-proteasome studies, apoptosis research, and cell cycle arrest studies. This guide connects reversible inhibitor handling with cytokine-responsive pulmonary epithelial assays and dose-sensitive osteoclast differentiation inhibition.

• DPPH Antioxidant Screening Workflow

  2026-08-28

  Build a reproducible DPPH workflow for rapid in vitro antioxidant screening, natural product comparison, and compound prioritization. The protocol combines plate-based colorimetry with orthogonal assays and UPLC-MS/MS so radical-scavenging results become more useful for high-throughput antioxidant screening and lead discovery.

• ERAD Hijacking for TM Protein Degradation

  2026-08-28

  Song et al. introduce ERAD-engaging chimeras (ERADECs), a small-molecule strategy that redirects transmembrane proteins to the ER-associated degradation pathway. By using desonide to recruit the ER E3 ligase SYVN1, the study achieves highly effective PD-L1 degradation and demonstrates tumor-suppression activity, while also extending the concept to mutant HTT.

• CLEC5A and ISG20 in Atherosclerosis: Causal Evidence

  2026-08-27

  Zhang et al. integrated GEO transcriptomic data, eQTL evidence, Mendelian randomization, and experimental validation to identify CLEC5A and ISG20 as genes associated with atherosclerosis risk. The study gives particular mechanistic attention to ISG20, linking its increased expression with macrophage lipid accumulation and inflammatory features in cellular and ApoE–/– mouse models.

• Vasopressin Analogues: Findings from a 2022 Review

  2026-08-26

  Glavaš and colleagues present an integrative review of vasopressin biology, receptor pharmacology, and the design of peptide and non-peptide analogues with distinct therapeutic profiles. The article shows how lypressin, desmopressin, terlipressin, and related compounds address different limitations of native vasopressin while also identifying important translational gaps in receptor selectivity, metabolic stability, and emerging antiviral applications.

• Azathramycin A: From Degradation to TB Assays

  2026-08-26

  Azathramycin A is a macrolide antibiotic and ribosome-binding research compound with unusual value as both a tuberculosis assay probe and azithromycin degradation marker. This guide develops a stability-aware workflow and explains how PK/PD evidence from gamithromycin can inform, but not replace, direct Azathramycin A experiments.

• Amikacin (BAY416651) in Resistance Assays

  2026-08-25

  Amikacin (BAY416651) is a mechanistically informative bacterial protein synthesis inhibitor for studying aminoglycoside susceptibility alongside carbapenemase gene transmission. This guide shows how to connect phenotype, enzyme-mediated resistance, plasmid localization, and assay reproducibility without overinterpreting genomic data.

• Octyl-α-ketoglutarate: A Causal Assay Tool

  2026-08-25

  Octyl-α-ketoglutarate is a cell-permeable prolyl hydroxylase substrate for dissecting HIF-1α regulation. This guide develops a causal assay framework that separates α-ketoglutarate availability, PHD activity, and broader metabolic effects in TCA cycle and IDH studies.

• OM-MSCs Relieve Golgi Stress After Stroke

  2026-08-24

  The 2021 reference study identifies a mechanistic link between olfactory mucosa mesenchymal stem cells (OM-MSCs), pigment epithelium-derived factor (PEDF), and Golgi apparatus protection after cerebral ischemia/reperfusion injury. Using complementary cellular and rat models, the authors show that OM-MSC-derived PEDF activates PI3K/Akt/mTOR signaling, reducing oxidative stress, calcium dysregulation, Golgi fragmentation, and excessive autophagy.

• Azathramycin A: Mtb Ribosome Research Guide

  2026-08-24

  Azathramycin A is a macrolide antibiotic research compound described as a Mycobacterium tuberculosis ribosome binder and bacterial protein synthesis inhibitor. Its documented physicochemical profile supports controlled in vitro tuberculosis research, while the available comparator evidence does not establish clinical efficacy or direct activity in Mtb.

8070 records 1/538 page Next 12345 下5页 Last page